Cargando…

Acute and cumulative effects of carboplatin on renal function.

Carboplatin, a cisplatinum analogue, has no reported nephrotoxicity in phase I/II studies, assessed by creatinine clearance. We prospectively determined renal function in 10 untreated lung cancer patients with normal baseline renal function, treated with carboplatin 400 mg m-2 day 1 and vincristine...

Descripción completa

Detalles Bibliográficos
Autores principales: Sleijfer, D. T., Smit, E. F., Meijer, S., Mulder, N. H., Postmus, P. E.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1989
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247337/
https://www.ncbi.nlm.nih.gov/pubmed/2679841
_version_ 1782150960463740928
author Sleijfer, D. T.
Smit, E. F.
Meijer, S.
Mulder, N. H.
Postmus, P. E.
author_facet Sleijfer, D. T.
Smit, E. F.
Meijer, S.
Mulder, N. H.
Postmus, P. E.
author_sort Sleijfer, D. T.
collection PubMed
description Carboplatin, a cisplatinum analogue, has no reported nephrotoxicity in phase I/II studies, assessed by creatinine clearance. We prospectively determined renal function in 10 untreated lung cancer patients with normal baseline renal function, treated with carboplatin 400 mg m-2 day 1 and vincristine 2 mg day 1 and 8 every 4 weeks (max. five cycles) by means of clearance studies with 125I-sodium thalamate and 131I-hippurate to determine GFR and ERPF respectively. Tubular damage was monitored by excretion of tubular enzymes and relative beta 2-microglobulin clearance. During the first course no changes in renal function were seen. After the second course a significant fall in GFR and ERPF started, ultimately leading to a median decrease in GFR of 19.0% (range 6.8-38.7%) and in ERPF of 14% (range 0-38.9%). No increases in the excretion of tubular enzymes or changes in the relative beta 2-microglobulin clearances were seen. We conclude from our data that carboplatin causes considerable loss of renal function. Monitoring renal function in patients treated with multiple courses of carboplatin is warranted.
format Text
id pubmed-2247337
institution National Center for Biotechnology Information
language English
publishDate 1989
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-22473372009-09-10 Acute and cumulative effects of carboplatin on renal function. Sleijfer, D. T. Smit, E. F. Meijer, S. Mulder, N. H. Postmus, P. E. Br J Cancer Research Article Carboplatin, a cisplatinum analogue, has no reported nephrotoxicity in phase I/II studies, assessed by creatinine clearance. We prospectively determined renal function in 10 untreated lung cancer patients with normal baseline renal function, treated with carboplatin 400 mg m-2 day 1 and vincristine 2 mg day 1 and 8 every 4 weeks (max. five cycles) by means of clearance studies with 125I-sodium thalamate and 131I-hippurate to determine GFR and ERPF respectively. Tubular damage was monitored by excretion of tubular enzymes and relative beta 2-microglobulin clearance. During the first course no changes in renal function were seen. After the second course a significant fall in GFR and ERPF started, ultimately leading to a median decrease in GFR of 19.0% (range 6.8-38.7%) and in ERPF of 14% (range 0-38.9%). No increases in the excretion of tubular enzymes or changes in the relative beta 2-microglobulin clearances were seen. We conclude from our data that carboplatin causes considerable loss of renal function. Monitoring renal function in patients treated with multiple courses of carboplatin is warranted. Nature Publishing Group 1989-07 /pmc/articles/PMC2247337/ /pubmed/2679841 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Sleijfer, D. T.
Smit, E. F.
Meijer, S.
Mulder, N. H.
Postmus, P. E.
Acute and cumulative effects of carboplatin on renal function.
title Acute and cumulative effects of carboplatin on renal function.
title_full Acute and cumulative effects of carboplatin on renal function.
title_fullStr Acute and cumulative effects of carboplatin on renal function.
title_full_unstemmed Acute and cumulative effects of carboplatin on renal function.
title_short Acute and cumulative effects of carboplatin on renal function.
title_sort acute and cumulative effects of carboplatin on renal function.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247337/
https://www.ncbi.nlm.nih.gov/pubmed/2679841
work_keys_str_mv AT sleijferdt acuteandcumulativeeffectsofcarboplatinonrenalfunction
AT smitef acuteandcumulativeeffectsofcarboplatinonrenalfunction
AT meijers acuteandcumulativeeffectsofcarboplatinonrenalfunction
AT muldernh acuteandcumulativeeffectsofcarboplatinonrenalfunction
AT postmuspe acuteandcumulativeeffectsofcarboplatinonrenalfunction